These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37318724)

  • 21. Nasopharyngeal carcinoma.
    Kamran SC; Riaz N; Lee N
    Surg Oncol Clin N Am; 2015 Jul; 24(3):547-61. PubMed ID: 25979399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
    BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cancers of the upper aerodigestive tract: the particular case of nasopharyngeal cancer].
    Ferrand FR; Busson P
    Rev Prat; 2022 Dec; 72(10):1099-1104. PubMed ID: 36891793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.
    Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY
    Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Yeo BSY; Lee RS; Lim NE; Tan E; Jang IJH; Toh HC; Lim CM
    Oral Oncol; 2024 May; 152():106786. PubMed ID: 38615584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
    Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
    Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
    Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
    Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.
    Le QT; Colevas AD; O'Sullivan B; Lee AWM; Lee N; Ma B; Siu LL; Waldron J; Lim CM; Riaz N; Lynn J; Malik S
    J Natl Cancer Inst; 2019 Jul; 111(7):655-663. PubMed ID: 30912808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic Association of Hepatitis B Surface Antigen and Plasma Epstein-Barr Virus DNA Load on Distant Metastasis in Patients With Nasopharyngeal Carcinoma.
    Li H; Cao D; Li S; Chen B; Zhang Y; Zhu Y; Luo C; Lin W; Huang W; Ruan G; Zhang R; Li J; Liu L
    JAMA Netw Open; 2023 Feb; 6(2):e2253832. PubMed ID: 36757699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Glypican-4 Gene Polymorphism rs1048369 and Susceptibility to Epstein-Barr Virus-Positive and -Negative Nasopharyngeal Carcinoma in Northern China.
    Liu S; Liu W; Zhao D; Zhang Y; Zhao Z; Luo B
    Oncol Res Treat; 2019; 42(11):572-579. PubMed ID: 31522169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
    Shi M; Sun D; Ma X; Liu J; Zhang Y; Liu T; Chen X; Mo S; Zhao Y; Zhang L
    Hum Vaccin Immunother; 2023 Dec; 19(3):2294579. PubMed ID: 38111107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
    PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
    Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
    Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
    Chia WK; Teo M; Wang WW; Lee B; Ang SF; Tai WM; Chee CL; Ng J; Kan R; Lim WT; Tan SH; Ong WS; Cheung YB; Tan EH; Connolly JE; Gottschalk S; Toh HC
    Mol Ther; 2014 Jan; 22(1):132-9. PubMed ID: 24297049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.
    Huang J; Harris E; Lorch J
    Oral Oncol; 2022 Dec; 135():106083. PubMed ID: 36332445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
    Nickles E; Dharmadhikari B; Yating L; Walsh RJ; Koh LP; Poon M; Tan LK; Wang LZ; Ang Y; Asokumaran Y; Chong WQ; Huang Y; Loh KS; Tay J; Soo R; Koh M; Ho LP; Chan M; Niam M; Soh M; Luah YH; Lim CM; Kaliaperumal N; Au VB; Talib NBSN; Sng R; Connolly JE; Goh BC; Schwarz H
    Cancer Immunol Immunother; 2022 Jun; 71(6):1531-1543. PubMed ID: 34661709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.